[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1007089T3 - Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose - Google Patents

Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose

Info

Publication number
DK1007089T3
DK1007089T3 DK97903837T DK97903837T DK1007089T3 DK 1007089 T3 DK1007089 T3 DK 1007089T3 DK 97903837 T DK97903837 T DK 97903837T DK 97903837 T DK97903837 T DK 97903837T DK 1007089 T3 DK1007089 T3 DK 1007089T3
Authority
DK
Denmark
Prior art keywords
thrombosis
humanized
treatment
antibodies against
against factor
Prior art date
Application number
DK97903837T
Other languages
Danish (da)
English (en)
Inventor
Giora Zeev Feuerstein
Michael Neal Blackburn
William Robert Church
Mitchell Stuart Gross
Andrew John Nichols
Eduardo Agustin Padlan
Arunbhai Haribhai Patel
Daniel Robert Sylvester
Original Assignee
Univ Vermont
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont, Smithkline Beecham Corp filed Critical Univ Vermont
Application granted granted Critical
Publication of DK1007089T3 publication Critical patent/DK1007089T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK97903837T 1996-01-17 1997-01-17 Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose DK1007089T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
DK1007089T3 true DK1007089T3 (da) 2006-10-09

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97903837T DK1007089T3 (da) 1996-01-17 1997-01-17 Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose

Country Status (26)

Country Link
US (5) US6005091A (no)
EP (2) EP1832297A1 (no)
JP (2) JP2000503210A (no)
KR (1) KR100553629B1 (no)
CN (1) CN1213312A (no)
AR (1) AR005658A1 (no)
AT (1) ATE330630T1 (no)
AU (1) AU706397B2 (no)
BR (1) BR9707049A (no)
CZ (1) CZ299452B6 (no)
DE (1) DE69736197T2 (no)
DK (1) DK1007089T3 (no)
ES (1) ES2267131T3 (no)
HK (1) HK1029513A1 (no)
HU (1) HU225903B1 (no)
ID (1) ID17156A (no)
IL (1) IL125380A0 (no)
MA (1) MA24512A1 (no)
MX (1) MX9805810A (no)
NO (1) NO983284L (no)
NZ (2) NZ501215A (no)
PL (1) PL187274B1 (no)
PT (1) PT1007089E (no)
SI (1) SI1007089T1 (no)
TR (1) TR199801390T2 (no)
WO (1) WO1997026010A1 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP1001991A4 (en) * 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
PT1095143E (pt) * 1998-05-08 2008-11-28 Sanquin Bloedvoorziening Inibidor para o diagnóstico e tratamento de doentes com hemofilia a
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES
EP1127148B1 (en) * 1998-10-31 2012-08-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
CA2381125C (en) * 1999-07-14 2013-04-23 D. Collen Research Foundation Vzw Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
EP2322648A1 (en) * 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
DE60236386D1 (de) 2001-01-11 2010-07-01 D Collen Res Foundation Vzw Verfahren und pharmazeutische Zusammensetzung zur Vorbeugung und/oder Behandlung des Syndroms der systemischen entzündlichen Reaktion
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
ATE415472T1 (de) * 2001-06-12 2008-12-15 Chemo Sero Therapeut Res Inst Humanantikörper gegen blutgerinnungsfaktor viii
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
AU2004264265C1 (en) 2003-08-14 2012-06-28 Thrombogenics Nv Antibodies against factor VIII with modified glycosylation in the variable region
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1693448A4 (en) * 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
EP2185592B1 (en) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
DK2644698T3 (en) 2010-11-17 2018-01-22 Chugai Pharmaceutical Co Ltd MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9771417B2 (en) 2014-08-07 2017-09-26 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP7022081B2 (ja) 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
CA3035327A1 (en) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
KR20200015943A (ko) 2017-06-15 2020-02-13 캔설 어드밴스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AU2018338859A1 (en) 2017-09-29 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
EP4015538A1 (en) 2018-12-21 2022-06-22 Kymab Limited Fixaxfx bispecific antibody with common light chain
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
ATE197590T1 (de) * 1992-08-27 2000-12-15 Sanquin Bloedvoorziening Antikoerper spezifisch fur ein haemostatisches protein; seine verwendung zur isolation von intaktem protein; haemostatische zusammensetzungen ohne proteolytische spaltprodukte des proteins
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
KR100553629B1 (ko) 2006-10-04
PL187274B1 (pl) 2004-06-30
ES2267131T3 (es) 2007-03-01
HU225903B1 (en) 2007-12-28
WO1997026010A1 (en) 1997-07-24
CN1213312A (zh) 1999-04-07
PL327929A1 (en) 1999-01-04
BR9707049A (pt) 2000-10-24
PT1007089E (pt) 2006-11-30
US6391299B1 (en) 2002-05-21
HUP9900396A2 (hu) 1999-05-28
DE69736197D1 (de) 2006-08-03
AU1830897A (en) 1997-08-11
CZ222598A3 (cs) 2000-01-12
US6005091A (en) 1999-12-21
HUP9900396A3 (en) 2001-10-29
AU706397B2 (en) 1999-06-17
US20070224198A1 (en) 2007-09-27
JP2000503210A (ja) 2000-03-21
NZ331014A (en) 2000-01-28
MA24512A1 (fr) 1998-12-31
EP1007089A4 (en) 2003-04-16
IL125380A0 (en) 1999-03-12
NO983284L (no) 1998-09-16
MX9805810A (es) 1998-11-30
EP1832297A1 (en) 2007-09-12
HK1029513A1 (en) 2001-04-06
ID17156A (id) 1997-12-04
US20020146411A1 (en) 2002-10-10
ATE330630T1 (de) 2006-07-15
AR005658A1 (es) 1999-07-14
NO983284D0 (no) 1998-07-16
JP2007325602A (ja) 2007-12-20
US20070003553A1 (en) 2007-01-04
SI1007089T1 (sl) 2006-12-31
EP1007089B1 (en) 2006-06-21
NZ501215A (en) 2001-04-27
DE69736197T2 (de) 2007-06-21
CZ299452B6 (cs) 2008-07-30
EP1007089A1 (en) 2000-06-14
KR19990077329A (ko) 1999-10-25
TR199801390T2 (xx) 1998-12-21

Similar Documents

Publication Publication Date Title
DK1007089T3 (da) Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
CY2006007I1 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
DK0830864T3 (da) Kombinationsbehandling til behandling af psykoser
ID16493A (id) Perlakuan bahan yang mengandung padatan yang diambil dari efluen
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DK0914103T3 (da) Behandling af hæmoglobinopati
DK0812845T3 (da) Fremgangsmåde til fremstilling af sildenafil
DK0861081T3 (da) Anvendelse af epinastin til behandling af smerter
DK0937016T3 (da) Behandling af kulbrintegas
FI97923B (fi) Portaittain säädettävä suodatin
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DK0841946T4 (da) Metoder til behandling af allergisk astma
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
DK0986376T3 (da) Anvendelse af en oligosacchardi-inhibitor af faktor Xa i kombination med en blodplade-antiaggregant til behandling af arteriel trombose
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
DK0650652T3 (da) Fremgangsmåde til implementering af kobling i tids- eller rumdomænet
DK0928183T3 (da) Anvendelse af 1-hydroxy-2-pyridoner til behandling af seborrhoisk dermatitis
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
FI961985A0 (fi) Oscillatorkrets
KR960014315A (ko) 녹방지 수차단제 및 이를 사용한 헹굼 방법
DE69412178D1 (de) Apparat zur Behandlung von Lagen
FI961986A0 (fi) Oscillatorkrets